Dacomitinib Impurity 2 | CAS 179552-75-1 - Request Quote
Dacomitinib Impurity 2
| SZ CAT No: | SZ-D071005 |
| CAS No | 179552-75-1 |
| Mol.F. | C15H12ClFN4O |
| Mol.Wt. | 318.7 |
| Inv. Status | Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Dacomitinib Impurity 2 is chemically N4-(3-chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine. Dacomitinib Impurity 2 is supplied with detailed characterization data compliant with regulatory guideline. Dacomitinib Impurity 2 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Dacomitinib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 179552-75-1
Purchase 179552-75-1
Order 179552-75-1
Enquire 179552-75-1
price of 179552-75-1
179552-75-1 Supplier
179552-75-1 Manufacturer
179552-75-1 Exporter
buy high quality Dacomitinib Impurity 2
Purchase Dacomitinib Impurity 2
Dacomitinib Impurity 2 suppliers
Dacomitinib Impurity 2 manufacturers
Dacomitinib Impurity 2 price
Order Dacomitinib Impurity 2
Enquire Dacomitinib Impurity 2
Dacomitinib Impurity 2 cost
Dacomitinib Impurity 2 Supplier
Dacomitinib Impurity 2 Distributor
Dacomitinib Impurity 2 for Method Validation
Dacomitinib Reference Standard
Dacomitinib Impurity 2 for ANDA Filing
Dacomitinib Impurity 2 for Forced Degradation Studies
Dacomitinib Impurity 2 Identification Standards
Dacomitinib Impurity 2 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.